Advanced search
Publication Cover
Diabetic Foot & Ankle Volume 9, 2018 - Issue 1
Journal homepage
1,550
Views
6
CrossRef citations to date
0
Altmetric
Trend Article

Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers

Martin Romero PradaPublic Health in Fundacion Salutia, Center in Health Economics Investigator, Bogotá D.C., ColombiaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-6158-6090View further author information
ORCID Icon,
Carolina RoaPublic Health in Fundacion Salutia, Center in Health Economics Investigator, Bogotá D.C., ColombiaView further author information
,
Pamela AlfonsoPublic Health in Fundacion Salutia, Center in Health Economics Investigator, Bogotá D.C., ColombiaView further author information
,
German AceroPublic Health in Fundacion Salutia, Center in Health Economics Investigator, Bogotá D.C., ColombiaView further author information
,
Lina HuérfanoPublic Health in Fundacion Salutia, Center in Health Economics Investigator, Bogotá D.C., ColombiaView further author information
&
David Vivas-ConsueloHealth Economics and management, Universitat Politècnica de València (UPV), Valencia, EspañaORCID Iconhttp://orcid.org/0000-0003-2945-7525View further author information
ORCID Icon
Article: 1480249 | Received 07 Nov 2017, Accepted 16 May 2018, Published online: 26 Jun 2018

References

  • Nehring P, Mrozikiewicz-Rakowska B, Krzyżewska M, et al. Diabetic foot risk factors in type 2 diabetes patients: a cross-sectional case control study. J Diabetes Metab Disord [Internet]. 2014;13:79. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4128535&tool=pmcentrez&rendertype=abstract
  • Mesa Perez JA, Vitarella G, Rosas Guzman J. Guías ALAD de Pie Diabético. Rev ALAD. 2010;XVIII(2):73–85.
  • Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Ther [Internet]. 2012;3(1):4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22529027
  • Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, et al. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719–1724.
  • Tirado RA del C, López JAF, Tirado FJ del C. Guía de práctica clínica en el pie diabético. Arch Med. 2014;10(1):1–17.
  • Al-Rubeaan K, Al Derwish M, Ouizi S, et al. Diabetic foot complications and their risk factors from a large retrospective cohort study. PLoS One. 2015;10(5):1–17.
  • NICE. Diabetic foot problems : prevention and management. NICE Guidel [Internet]. 2015;(August). Available from: http://www.nice.org.uk/guidance/ng19/resources/diabetic-foot-problems-prevention-and-management-1837279828933
  • Júbiz PY, Márquez SG, Márquez ZA,. Guías colombianas para la prevención, diagnóstico y tratamiento del pie diabético 2012. COLPEDIS, Grup Colomb Pie Diabético. 2012;1:98. . p. 1–7.
  • Esquirol J, Vila H. Factor de crecimiento epidérmico, innovación y seguridad Factor de crecimiento epide. Med Clin. 2014;145(7).
  • Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: A randomized double-blinded controlled trial. Wound Repair Regen. 2014;22(4):497–503.
  • Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab. 2004;30:549–556.
  • Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: Multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6(6):432–443.
  • Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, et al. Intralesional injections of Citoprot-P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4(4):333–343.
  • Malyar N, Freisinger E, Meyborg M, et al. Amputations and mortality in in-hospital treated patients with peripheral artery disease and diabetic foot syndrome. J Diabetes Complications [Internet]. 2016; Available from: http://www.sciencedirect.com/science/article/pii/S1056872716300897
  • Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26(2):491–494.
  • Banco de la República. Tasa de cambio del peso colombiano (TRM) [Internet]. http://www.banrep.gov.co. 2016. p. 4. Available from: http://www.banrep.gov.co/es/trm
  • Moreno Viscaya M, Mejía Mejía A, Castro Jaramillo HE. Manual para la elaboración de evaluaciones económicas en salud. Instituto de Evaluación Tecnológia en Salud. 2014.
  • Martí-Carvajal AJ, Gluud C, Nicola S, et al. Growth factors for treating diabetic foot ulcers. Vol. 2015, Cochrane Database of Systematic Reviews. 2015.
  • Acosta-reyes MR, López A, Álvarez O, González AM, et al. Evaluación económica del uso de factor de crecimiento epidérmico recombinante humano (FCErh) en población mexicana con pie diabético en el Sector Salud. 2014;81(3):147–53.
  • Rodriguez D, Erika A. Estudio y análisis comparativo de mercados de prótesis médicas de fabricación colombiana para la exportación a China o Estados Unidos. Univ San Buenaventura [Internet]. 2007; Available from: http://biblioteca.usbbog.edu.co:8080/Biblioteca/BDigital/40980.pdf
  • López-saura PA. Intralesional Human Recombinant Epidermal Growth Factor for the Treatment of Advanced Diabetic Foot Ulcer : From Proof of Concept to Confirmation of the Efficacy and Safety of the Procedure. 2006.
  • Reiber, G. E. “The epidemiology of diabetic foot problems.” Diabetic medicine: a journal of the British Diabetic Association13 (1996): p S6.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.